NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Octreotide

Last Revision: July 20, 2020.

Estimated reading time: 1 minute

CASRN: 83150-76-9

image 135012855 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

The excretion of octreotide into breastmilk has not been studied. However, because it has a high molecular weight of 1019 daltons it is likely to be poorly excreted into breastmilk. It is poorly absorbed orally and has been safely administered directly to infants by injection, so it is unlikely to adversely affect the breastfed infant.[1] At least two infants have been successfully breastfed with no adverse effects reported. Until more data are available, octreotide should be used in nursing mothers with careful infant monitoring, especially if the infant is under 2 months of age.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

One mother was treated for acromegaly during pregnancy and postpartum with octreotide (dose not stated). She breastfed (extent not stated) her infant for 4 months with no apparent problems noted in the infant.[2]

Effects on Lactation and Breastmilk

A pregnant woman with acromegaly started long-acting octreotide 10 mg monthly at 12 weeks gestation. After delivery, she breastfed her until 6 weeks postpartum when she required an increase in octreotide LAR to 20 mg monthly. She continued to breastfeed successfully on octreotide.[3]

References

1.
van der Steen I, van Albada ME, Mohnike K, et al. A multicenter experience with long-acting somatostatin analogues in patients with congenital hyperinsulinism. Horm Res Paediatr. 2018;89:82–9. [PubMed: 29241206]
2.
Colao A, Merola B, Ferone D, et al. Acromegaly. J Clin Endocrinol Metab. 1997;82:2777–81. [PubMed: 9284694]
3.
Assal A, Malcolm J, Lochnan H, et al. Preconception counselling for women with acromegaly: More questions than answers. Obstet Med. 2016;9:9–14. [PMC free article: PMC4950431] [PubMed: 27512484]

Substance Identification

Substance Name

Octreotide

CAS Registry Number

83150-76-9

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents, Hormonal

Gastrointestinal Agents

Somatostatin Analogs

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

  • Review Indium In 111 Pentetreotide[Drugs and Lactation Database (...]
    Review Indium In 111 Pentetreotide
    . Drugs and Lactation Database (LactMed). 2006
  • Review Pramlintide[Drugs and Lactation Database (...]
    Review Pramlintide
    . Drugs and Lactation Database (LactMed). 2006
  • Review Lanreotide[Drugs and Lactation Database (...]
    Review Lanreotide
    . Drugs and Lactation Database (LactMed). 2006
  • Review Pasireotide[Drugs and Lactation Database (...]
    Review Pasireotide
    . Drugs and Lactation Database (LactMed). 2006
  • Review Liraglutide[Drugs and Lactation Database (...]
    Review Liraglutide
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...